Frequent alterations in cytoskeleton remodelling genes in primary and metastatic lung adenocarcinomas

Nature Communications

Volumn 6, Issue , 2015, Pages

  Wu, Kui ^a,b,c,d,e   Zhang, Xin ^b,c,d   Li, Fuqiang ^a   Xiao, Dakai ^b,c   Hou, Yong ^a,e   Zhu, Shida ^a,e   Liu, Dongbing ^a   Ye, Xiaofei ^a,f   Ye, Mingzhi ^a,g   Yang, Jie ^a   Shao, Libin ^a   Pan, Hui ^b,c   Lu, Na ^a   Yu, Yuan ^a   Liu, Liping ^b,c   Li, Jin ^b,c   Huang, Liyan ^b,c   Tang, Hailing ^b,c   Deng, Qiuhua ^b,c   Zheng, Yue ^a   Peng, Lihua ^a   Liu, Geng ^a   Gu, Xia ^b   He, Ping ^b   Gu, Yingying ^b,c   Lin, Weixuan ^b   He, Huiming ^b   Xie, Guoyun ^a   Liang, Han ^a   An, Na ^a   Wang, Hui ^a   Teixeira, Manuel ^h   Vieira, Joana ^h   Liang, Wenhua ^b,c,d   Zhao, Xin ^a   Peng, Zhiyu ^a,g   Mu, Feng ^a,i   Zhang, Xiuqing ^a,g   Xu, Xun ^a   Yang, Huanming ^a,j   Kristiansen, Karsten ^a,b   Zhong, Nanshan ^c,d   Wang, Jun ^a,e   Pan Hammarström, Qiang ^a,f   He, Jianxing ^b,c,d   Wang, Jian ^a,j   more..

^a BGI SHENZHEN   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

^d National Clinical Research Center for Respiratory Disease   (China)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f KAROLINSKA INSTITUTE   (Sweden)

^g Guangzhou Key Laboratory of Cancer Trans Omics Research   (China)

^h PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

ⁱ BGI Wuhan ^*  (China)

^j ZHEJIANG UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; IQGAP3 PROTEIN; ITIH5 PROTEIN; K RAS PROTEIN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; LRP1B PROTEIN; MANNOSE RECEPTOR C TYPE 2; PIK3CA PROTEIN; PROTEIN; PROTEIN KINASE LKB1; PROTEIN P53; PTPRD PROTEIN; RHOPHILIN 2; SMAD2 PROTEIN; TRANSCRIPTION FACTOR GLI3; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

CYTOGENETICS; GENE EXPRESSION; MODELING; MOLECULAR ANALYSIS; RESPIRATORY DISEASE;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINESE; COHORT ANALYSIS; CYTOSKELETON; FEMALE; GENE AMPLIFICATION; GENE CONTROL; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HUMAN; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTATIC LUNG ADENOCARCINOMA; MOLECULAR PATHOLOGY; MUTATION; MUTATION RATE; MUTATIONAL ANALYSIS; PATHOGENESIS; PRIMARY TUMOR; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SOMATIC MUTATION; SURVIVAL TIME; ADENOCARCINOMA; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; LUNG TUMOR; METABOLISM; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

CHINA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; CYTOSKELETON; FEMALE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION;

EID: 84949570896     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms10131     Document Type: Article

References (64)

1. Jemal, A. et al. Global cancer statistics. CA Cancer J. Clin. 61, 69-90 (2011).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
3. Herbst, R. S., Heymach, J. V. & Lippman, S. M. Lung cancer. N. Engl. J. Med. 359, 1367-1380 (2008).
4. Imielinski, M. et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150, 1107-1120 (2012).
5. Pao, W. & Girard, N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 12, 175-180 (2011).
6. Pao, W. & Hutchinson, K. E. Chipping away at the lung cancer genome. Nat. Med. 18, 349-351 (2012).
7. Zhang, J. et al. Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing. Science 346, 256-259 (2014).
8. de Bruin, E. C. et al. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 346, 251-256 (2014).
9. Weir, B. A. et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 450, 893-898 (2007).
10. Ding, L. et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455, 1069-1075 (2008).
11. Cancer Genome Atlas Research Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature 511, 543-550 (2014).
12. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
13. Greulich, H. et al. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc. Natl Acad. Sci. USA 109, 14476-14481 (2012).
14. Ballantyne, A. D. & Garnock-Jones, K. P. Dabrafenib: first global approval. Drugs 73, 1367-1376 (2013).
15. Kwak, E. L. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 363, 1693-1703 (2010).
16. Bergethon, K. et al. ROS1 rearrangements define a unique molecular class of lung cancers. J. Clin. Oncol. 30, 863-870 (2012).
17. Drilon, A. et al. Response to Cabozantinib in patients with RET fusion-positive lung adenocarcinomas. Cancer Discov. 3, 630-635 (2013).
18. Vignot, S. et al. Next-generation sequencing reveals high concordance of recurrent somatic alterations between primary tumour and metastases from patients with non-small-cell lung cancer. J. Clin. Oncol. 31, 2167-2172 (2013).
19. Cibulskis, K. et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat. Biotechnol. 31, 213-219 (2013).
20. Rimmer, A. et al. Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applications. Nat. Genet. 46, 912-918 (2014).
21. Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415-421 (2013).
22. Zhao, Y. et al. Identification of somatic alterations in stage I lung adenocarcinomas by next-generation sequencing. Genes Chromosomes Cancer 53, 289-298 (2014).
23. Youn, A. & Simon, R. Identifying cancer driver genes in tumour genome sequencing studies. Bioinformatics 27, 175-181 (2011).
24. Kan, Z. et al. Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Res. 23, 1422-1433 (2013).
25. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
26. Pao, W. et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2, e17 (2005).
27. Peck, J. W., Oberst, M., Bouker, K. B., Bowden, E. & Burbelo, P. D. The RhoA-binding protein, rhophilin-2, regulates actin cytoskeleton organization. J. Biol. Chem. 277, 43924-43932 (2002).
28. Danussi, C. et al. RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. Cancer Res. 73, 5140-5150 (2013).
29. Bai, X. Y. et al. High expression of truncated GLI3 is associated with poor overall survival in patients with non-small cell lung cancer. Cancer Biomark. 13, 37-47 (2013).
30. Ishikawa, M. et al. Expression of the GLI family genes is associated with tumour progression in advanced lung adenocarcinoma. World J. Surg. Oncol. 12, 253 (2014).
31. Behrendt, N. et al. A urokinase receptor-associated protein with specific collagen binding properties. J. Biol. Chem. 275, 1993-2002 (2000).
32. Curino, A. C. et al. Intracellular collagen degradation mediated by uPARAP/Endo180 is a major pathway of extracellular matrix turnover during malignancy. J. Cell Biol. 169, 977-985 (2005).
33. Wienke, D. et al. The collagen receptor Endo180 (CD280) Is expressed on basal-like breast tumour cells and promotes tumour growth in vivo. Cancer Res. 67, 10230-10240 (2007).
34. Takahashi, S. et al. Downregulation of uPARAP mediates cytoskeletal rearrangements and decreases invasion and migration properties in glioma cells. J. Neurooncol. 103, 267-276 (2011).
35. Gai, X., Tu, K., Lu, Z. & Zheng, X. MRC2 expression correlates with TGFbeta1 and survival in hepatocellular carcinoma. Int. J. Mol. Sci. 15, 15011-15025 (2014).
36. Rodriguez-Teja, M. et al. Survival outcome and EMT suppression mediated by a lectin domain interaction of endo180 and CD147. Mol. Cancer Res. 13, 538-547 (2015).
37. Beroukhim, R. et al. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc. Natl Acad. Sci. USA 104, 20007-20012 (2007).
38. Gainor, J. F. et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin. Cancer Res. 19, 4273-4281 (2013).
39. Briggs, M. W. & Sacks, D. B. IQGAP proteins are integral components of cytoskeletal regulation. EMBO Rep. 4, 571-574 (2003).
40. White, C. D., Brown, M. D. & Sacks, D. B. IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis. FEBS Lett. 583, 1817-1824 (2009).
41. Tan, V. Y., Lewis, S. J., Adams, J. C. & Martin, R. M. Association of fascin-1 with mortality, disease progression and metastasis in carcinomas: a systematic review and meta-analysis. BMC Med. 11, 52 (2013).
42. Park, S. H. et al. Fascin1 expression in high-grade serous ovarian carcinoma is a prognostic marker and knockdown of fascin1 suppresses the proliferation of ovarian cancer cells. Int. J. Oncol. 44, 637-646 (2014).
43. Al-Alwan, M. et al. Fascin is a key regulator of breast cancer invasion that acts via the modification of metastasis-associated molecules. PLoS ONE 6, e27339 (2011).
44. Schmid, K. et al. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin. Cancer Res. 15, 4554-4560 (2009).
45. Monaco, S. E. et al. A comparison of EGFR and KRAS status in primary lung carcinoma and matched metastases. Hum. Pathol. 41, 94-102 (2010).
46. Jackson, E. L. et al. Analysis of lung tumour initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
47. Meuwissen, R., Linn, S. C., van der Valk, M., Mooi, W. J. & Berns, A. Mouse model for lung tumorigenesis through Cre/lox controlled sporadic activation of the K-Ras oncogene. Oncogene 20, 6551-6558 (2001).
48. Baldus, S. E. et al. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin. Cancer Res. 16, 790-799 (2010).
49. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
50. Adorno, M. et al. A Mutant-p53/Smad complex opposes p63 to empower TGFbeta-induced metastasis. Cell 137, 87-98 (2009).
51. Muller, P. A. et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 139, 1327-1341 (2009).
52. Morton, J. P. et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl Acad. Sci. USA 107, 246-251 (2010).
53. Weissmueller, S. et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signalling. Cell 157, 382-394 (2014).
54. Muller, P. A. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304-317 (2014).
55. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760 (2009).
56. McKenna, A. et al. The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297-1303 (2010).
57. Li, J. et al. CONTRA: copy number analysis for targeted resequencing. Bioinformatics 28, 1307-1313 (2012).
58. Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nat. Methods 8, 652-654 (2011).
59. Wang, K., Li, M. & Hakonarson, H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 38, e164 (2010).
60. Alexandrov, L. B., Nik-Zainal, S., Wedge, D. C., Campbell, P. J. & Stratton, M. R. Deciphering signatures of mutational processes operative in human cancer. Cell Rep. 3, 246-259 (2013).
61. Jia, W. et al. SOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data. Genome Biol. 14, R12 (2013).
62. Zhang, B., Kirov, S. & Snoddy, J. WebGestalt: an integrated system for exploring gene sets in various biological contexts. Nucleic Acids Res. 33, W741-W748 (2005).
63. Shannon, P. et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13, 2498-2504 (2003).
64. Croft, D. et al. Reactome: a database of reactions, pathways and biological processes. Nucleic Acids Res. 39, D691-D697 (2011).